Elanco Animal Health (NYSE:ELAN) Hits New 1-Year Low - Should You Sell?

Shares of Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $8.02 and last traded at $8.12, with a volume of 196559 shares. The stock had previously closed at $8.10.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on ELAN. UBS Group cut their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a report on Wednesday, February 26th. Stifel Nicolaus lowered their price objective on shares of Elanco Animal Health from $15.00 to $13.00 and set a "buy" rating on the stock in a research report on Monday, April 14th. Barclays decreased their target price on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Piper Sandler dropped their price target on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research note on Thursday, March 6th. Finally, Morgan Stanley lowered their target price on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 26th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $14.67.

Elanco Animal Health Trading Up 4.2 %

The business's 50 day moving average price is $10.26 and its 200-day moving average price is $11.83. The firm has a market capitalization of $4.19 billion, a price-to-earnings ratio of 21.11, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.01). The business had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm's revenue for the quarter was down 1.4% on a year-over-year basis. During the same period last year, the company earned $0.08 EPS. Equities analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Insider Activity at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius acquired 10,000 shares of Elanco Animal Health stock in a transaction dated Tuesday, March 11th. The stock was acquired at an average cost of $10.20 per share, for a total transaction of $102,000.00. Following the completion of the transaction, the director now owns 111,459 shares in the company, valued at approximately $1,136,881.80. This represents a 9.86 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.89% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. CoreCap Advisors LLC bought a new position in Elanco Animal Health in the 4th quarter valued at about $29,000. Wilmington Savings Fund Society FSB bought a new position in shares of Elanco Animal Health in the third quarter valued at approximately $35,000. NBC Securities Inc. acquired a new position in shares of Elanco Animal Health during the first quarter valued at approximately $40,000. Parallel Advisors LLC raised its holdings in Elanco Animal Health by 92.2% during the first quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock worth $41,000 after purchasing an additional 1,852 shares in the last quarter. Finally, Versant Capital Management Inc lifted its position in Elanco Animal Health by 65.9% in the first quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock worth $46,000 after purchasing an additional 1,740 shares during the period. 97.48% of the stock is owned by institutional investors and hedge funds.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.